There were no clear benefits of using faster insulin aspart in closed-loop insulin therapy and the closed-loop algorithm was better adjusted to the use of standard insulin aspart.
A glycated hemoglobin (HbA1c) target value of <6.5 percent does not offer additional protection against organ complications for patients with type 1 diabetes compared with a target of 6.5 to 6.9 percent.
Hepatic-directed vesicle insulin, a novel liver-targeted rapid-acting insulin formulation for type 1 diabetes, is noninferior to insulin lispro for improvement of HbA1c and is associated with a lower hypoglycemia risk in some patients.
Colophonium, a fast-acting adhesive and known sensitizing allergen, may cause dermatologic reactions in children using devices to manage diabetes.
ADO09, a coformulation of amylin analog pramlintide and A21G human insulin, is superior to insulin lispro for reducing postprandial blood glucose in patients with type 1 diabetes.
Highest rates reported among preschoolers, children, and adolescents aged younger than 15 years
There is a dose-dependent relationship between the amount of fat and postprandial glucose levels.
Researchers found approximately one-third of patients with type 1 diabetes and celiac disease were able to achieve sustained celiac-specific antibody negativity after celiac disease diagnosis.
Type 1 diabetes diagnosis is missed less frequently when patients present during childhood or adolescence, but unlike in adults, misdiagnosis in childhood is associated with an increased likelihood of diabetic ketoacidosis.
Children with type 1 diabetes have worse education and health outcomes than their peers.
Lexicon Pharmaceuticals announced new data from the phase 3 inTandem1 and inTandem2 studies of sotagliflozin in adult patients with type 1 diabetes.
Maternal blood glucose levels and body mass index are the most important modifiable risk factors for stillbirth in women with pre-pregnancy diabetes.
The FDA has granted Breakthrough Therapy designation to teplizumab (PRV-031; Provention Bio), for the prevention or delay of clinical T1D in those at risk of developing the disease.
Evidence to date suggests that the risk for all-cause dementia is 40% to 60% higher in patients with type 1 or type 2 diabetes.
In young patients with type 1 diabetes, phenotypes of body mass index and glycemic control are associated with patterns of early diabetes complications.
Researchers aimed to determine the optimal BP threshold to minimize the risk for coronary artery disease events in young patients with childhood-onset T1D.
Checkpoint inhibitor-associated autoimmune diabetes (CIADM) is a distinct pathophysiologic entity from type 1 diabetes.
Dapagliflozin was recently approved for T1D in Europe and Japan.
Measurement of serum apolipoprotein levels in apolipoprotein-defined lipoprotein subclasses may have an important role in predicting vascular complications in T1D.
There is a correlation between a high level of amyloid-producing Escherichia coli in the intestines and the initiation of autoimmunity and type 1 diabetes progression.